Weekly shot aims to get severe hemophilia patients moving more
NCT ID NCT05817812
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study is testing a new medicine called efanesoctocog alfa in about 90 people aged 12 and older with severe hemophilia A. Participants receive a weekly injection for 24 months to see if it helps them be more physically active and improves joint health. The study uses activity trackers and diaries to track bleeds, pain, and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A, SEVERE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site
Vienna, Austria
-
Investigational Site
Zagreb, Croatia
-
Investigational Site
Brno, Czechia
-
Investigational Site
Prague, Czechia
-
Investigational Site
Bordeaux, France
-
Investigational Site
Le Kremlin-Bicêtre, France
-
Investigational Site
Marseille, France
-
Investigational Site
Strasbourg, France
-
Investigational Site
Berlin, Germany
-
Investigational Site
Frankfurt, Germany
-
Investigational Site
Giessen, Germany
-
Investigational Site
Hamburg, Germany
-
Investigational Site
Athens, Greece
-
Investigational Site
Dublin, Ireland
-
Investigational Site
Catanzaro, Italy
-
Investigational Site
Florence, Italy
-
Investigational Site
Naples, Italy
-
Investigational Site
Parma, Italy
-
Investigational Site
Rome, Italy
-
Investigational Site
Utrecht, Netherlands
-
Investigational Site
Oslo, Norway
-
Investigational Site
Ljubljana, Slovenia
-
Investigational Site
Barcelona, Spain
-
Investigational Site
Madrid, Spain
-
Investigational Site
Oviedo, Spain
-
Investigational Site
Lund, Sweden
-
Investigational Site
Solna, Sweden
-
Investigational Site
Canterbury, United Kingdom
-
Investigational Site
Newcastle upon Tyne, United Kingdom
-
Investigational Site
Oxford, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.